Potentiation of the therapeutic activity of cyclophosphamide by an original N-acyldehydroalanine.
Research work is currently in progress with the aim of improving the efficacy and/or reducing the toxicity of cancer treatments. The present communication reports on the effect of an original molecule, N-(ortho-methoxyphenylacetyl)dehydroalanine, known as AD20. In a protocol in which L1210 leukaemic cells, AD20 and cyclophosphamide were injected i.p. into BDF1 mice, the association CP-AD20 was more active than CP alone at therapeutic or subtherapeutic doses of CP. If the doses of CP were higher than its optimum therapeutic dose, the association CP-AD20 was more toxic than CP alone. The positive effect of AD20 was also observed when AD20 was given i.v. or when the leukaemic cells were implanted s.c., CP always being injected i.p. Taking into account its low toxicity, AD20 exhibits interesting properties that could support its development as an adjuvant for cancer chemotherapy.
D000409:Alanine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000818:Animals; D002470:Cell Survival / Q000187:drug effects; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004357:Drug Synergism; D007939:Leukemia L1210 / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008811:Mice, Inbred DBA
C053274:AD 20; D003520:Cyclophosphamide; D000409:Alanine